EyePoint Pharmaceuticals, Inc., a biopharmaceutical company, has filed a Form 8-K report with the SEC on May 28, 2024, detailing recent corporate events. The company has updated its investor presentation and filed it as Exhibit 99.1, which includes information on its product candidates, particularly DURAVYU™, a treatment for wet age-related macular degeneration (wet AMD), and EYP-2301, a treatment for serious retinal diseases. The presentation highlights the completion of a Phase 2 clinical trial for DURAVYU™, which met all primary and secondary objectives, showing non-inferiority to aflibercept, a reduction in treatment burden, and a favorable safety profile. The company plans to initiate the first pivotal Phase 3 trial for DURAVYU™ in the second half of 2024. EyePoint Pharmaceuticals also reported a strong balance sheet with $299M in cash and investments as of March 31, 2023, and a cash runway through topline data in 2026 for the Phase 3 wet AMD pivotal trials.

EyePoint Pharmaceuticals, Inc., a biopharmaceutical company, has filed a Form 8-K report with the SEC on May 28, 2024, detailing recent corporate events. The company has updated its investor presentation and filed it as Exhibit 99.1, which includes information on its product candidates, particularly DURAVYU™, a treatment for wet age-related macular degeneration (wet AMD), and EYP-2301, a treatment for serious retinal diseases. The presentation highlights the completion of a Phase 2 clinical trial for DURAVYU™, which met all primary and secondary objectives, showing non-inferiority to aflibercept, a reduction in treatment burden, and a favorable safety profile. The company plans to initiate the first pivotal Phase 3 trial for DURAVYU™ in the second half of 2024. EyePoint Pharmaceuticals also reported a strong balance sheet with $299M in cash and investments as of March 31, 2023, and a cash runway through topline data in 2026 for the Phase 3 wet AMD pivotal trials.